Silencing HMGB1 expression inhibits adriamycin's heart toxicity via TLR4 dependent manner through MAPK signal transduction


Taskin E., Guven C., Kaya S. T. , Sariman M., EMRENCE Z. , Ekmekci S. S. , ...Daha Fazla

JOURNAL OF BUON, cilt.25, ss.554-565, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 25 Konu: 1
  • Basım Tarihi: 2020
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.554-565

Özet

Purpose: Adriamycin (APR) is a commonly used anti-cancer drug. ADR has toxic effects on cardiomyocytes and leads to heart failure. However, the underlying mechanism(s) by which ADR causes heart failure is still not clarified exactly. The aim of present study is to investigate whether ADR-induced heart failure is mediated via HMGB1/TLR4 to initiate the apoptosis through MAPK/AMPK pathways.